Braunwald N S, Brais M, Castaneda A
J Thorac Cardiovasc Surg. 1976 Oct;72(4):539-46.
Experimental studies carried out in our laboratory suggest that it is possible to develop a family of stent-supported tissue valve substitutes suitable for use in tissue and annuli of the hearts of small children in tissue annulus sizes ranging from 12 to 22 mm. Either glutaraldehyde-preserved, stent-supported primate tissue aortic valves or tissue leaflet valves constructed from dura mater preserved in 98 per cent glycerine can be used. In both instances, hemodynamics assessment of the valve substitutes in a mock circulation indicated that function was acceptable at the cardiac outputs normal for infants and children during the first few years of life. Stent-supported dura mater valves 16 nm. in diameter have been used to replace the mitral valve in 2 infants 7 and 8 months of age with complete atrioventricular canal defects and mitral regurgitation, one of whom survives with demonstratable satisfactory hemodynamic function of the valve substitute.
我们实验室进行的实验研究表明,有可能开发出一系列支架支撑的组织瓣膜替代品,适用于组织环尺寸在12至22毫米之间的小儿心脏组织和瓣环。可以使用戊二醛保存的、支架支撑的灵长类动物组织主动脉瓣,或由保存在98%甘油中的硬脑膜构建的组织瓣叶瓣膜。在这两种情况下,在模拟循环中对瓣膜替代品进行的血流动力学评估表明,在生命的最初几年,在婴儿和儿童正常的心输出量下,其功能是可以接受的。直径为16毫米的支架支撑硬脑膜瓣膜已被用于替换2名7个月和8个月大患有完全性房室通道缺损和二尖瓣反流的婴儿的二尖瓣,其中一名婴儿存活下来,瓣膜替代品的血流动力学功能令人满意。